Clinical Trial Detail

NCT ID NCT02343952
Title Consolidation Pembrolizumab (MK-3475), Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Nasser Hanna, M.D.
Indications

lung non-small cell carcinoma

Therapies

Pembrolizumab

Age Groups: adult

No variant requirements are available.